Home About Us Writing a Scientific Article Author's Instruction Contact us



/  /    MRJMMS Home   /   /    About MRJMMS    /  /    Submit Manuscripts    /  /      Call For Articles      / /     Editorial Board     / /    Archive     / /    Author's Guide  /  /


January 2018 Vol. 6 No.1

Other viewing option

• Full text
Reprint (PDF) (440 KB)

Search Pubmed for articles by:

Akyuva Y
Sirin DY

Other links:
PubMed Citation
Related articles in PubMed



Merit Research Journal of Medicine and Medical Sciences (ISSN: 2354-323X) Vol. 6(1) pp. 006-015, January, 2018 

Copyright © 2018 Merit Research Journals

Original Research Article

Will intervertebral disc diseases be prevented by siRNA or miRNA-based genomic treatment modalities?


Yener AKYUVA1, Numan KARAARSLAN2*, Ibrahim YILMAZ3, Tezcan CALISKAN2 and Duygu Yasar SIRIN4


1M.D., Gaziosmanpasa Taksim Training and Research Hospital, Department of Neurosurgery, 34433, Istanbul, Turkey
2Assist. Prof. M.D., Namik Kemal University School of Medicine, Department of Neurosurgery, 59100, Tekirdag, Turkey
3Medical Pharmacologist, pharmacist, Istanbul Medipol University School of Medicine, Department of Medical Pharmacology, 34810, Istanbul, Turkey
4Assist. Prof. Ph.D., Namik Kemal University, Faculty of Arts and Sciences, Department of Molecular Biology and Genetics, 59030, Tekirdag, Turkey

*Corresponding Author’s É-mail: numikara@yahoo.com
Phone: +9028 2250 5500

Accepted January 05, 2018




In the present study, a systematic review of experimental research carried out by drug delivery systems that allow for drug release in which oligonucleotides are imbrued, such as small interfering-/micro ribonucleic acids, was conducted. The data obtained after an electronic database query with no language limitation were evaluated using statistical methods. Results were shown as frequency. There was no research found that described successfully imbrued oligonucleotides into drug delivery systems that could be used to prevent intervertebral disc degeneration. There is a high possibility that trial target therapies might have a positive effect on nucleus pulposus cell regeneration, which is damaged most in the disc during intervertebral disc degeneration; however, these designs, whose invitro release kinetics have been reported, need to be tested invivo in living subjects after they have been tested for surgical techniques to fill this gap in the literature.

Key Words: Antisense oligonucleotide therapy, Drug delivery systems, Intervertebral disc degeneration, miRNA; nucleus pulposus cell, Post transcriptional gene silencing, siRNA






Merit Research Journals© 2018 || Advertisement | Privacy policy.